Reply
Christophe Rodriguez, Stéphane Chevaliez, Jean‐Michel Pawlotsky – 1 August 2013
Healthcare costs associated with hepatocellular carcinoma and the value of care
Lorenzo G. Mantovani, Mario Strazzabosco – 31 July 2013
Sublethal heat treatment promotes epithelial‐mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma
Jiwen Cheng, MuXing Li, Yi Lv – 31 July 2013
Chronic hepatitis E in an immunocompetent patient: A case report
Priya Grewal, Saleem Kamili, David Motamed – 31 July 2013
Healthcare costs associated with hepatocellular carcinoma and the value of care
Lorenzo G. Mantovani, Mario Strazzabosco – 31 July 2013
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case‐control study
Cristina Ripoll, Joan Genescà, Isis K. Araujo, Isabel Graupera, Salvador Augustin, Marta Tejedor, Isabel Cirera, Carles Aracil, Margarita Sala, Manuel Hernandez‐Guerra, Elba Llop, Angels Escorsell, Maria Vega Catalina, Nuria Cañete, Agustin Albillos, Càndid Villanueva, Juan G. Abraldes, Rafael Bañares, Jaime Bosch – 31 July 2013 – Outcome of variceal bleeding (VB) in patients with hepatocellular carcinoma (HCC) is unknown. We compared outcomes after VB in patients with and without HCC. All patients with HCC and esophageal VB admitted between 2007 and 2010 were included.
Flipping the switch
31 July 2013
Recurrence of hepatopulmonary syndrome post–orthotopic liver transplantation in a patient with noncirrhotic portal hypertension
Stephen Casey, Anthony Schelleman, Peter Angus – 31 July 2013
Fra, Fra Away: The complex role of activator protein 1 in liver injury
David A. Brenner – 31 July 2013
Insulin resistance, telaprevir, and virological response in hepatitis C: The debate must go on
Manuel Romero‐Gómez, José A. Campo – 31 July 2013